Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Divides R&D, Expects More Late-Stage Studies In 2021

CSO To Retire, And Rybelsus Sales Grow

Executive Summary

Novo Nordisk’s newer GLP1 products for diabetes, Ozempic and Rybelsus, drove the company’s sales growth in 2020, and with its CSO retiring after a two-decade shift, internal appointments are made to lead a reorganized R&D function.

You may also be interested in...



Five New EU Filings Leave Starting Blocks at EMA

There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.

13 New Drugs Pass Muster At The EMA, Dexamethasone Withdrawal Explained

New products from Paion, Arvelle, Incyte and many others have been recommended for approval by the European Medicines Agency. Meanwhile, the agency has explained why the EU marketing authorization application for Dexamethasone Taw, for treating COVID-19 patients, was withdrawn.

Novo Nordisk Takes The Plunge Into Alzheimer's With Phase III Semaglutide Trial

Analysis of cardiovascular studies show GLP-1 drugs are associated with a 53% reduced risk of developing Alzheimer’s disease.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel